Downstream Effects of Market Changes on Inhalers: Impacts on Individuals With Chronic Lung Disease

REFERENCES

1. 1.↵
   Institute of Medicine. Committee on a national surveillance system for cardiovascular and chronic lung disease. A nationwide framework for surveillance of cardiovascular and chronic lung diseases. Washington (District of Columbia): National Academies of Press (US); 2011.
2. 2.↵
   GBD Chronic Respiratory Disease Collaborators. Prevalence of attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med 2020;8(6):585-596.

   OpenUrlPubMed
3. 3.↵
   American Lung Association. New program offers critical resources to the 34 million Americans living with lung disease. Updated January 2023. Available at: https://www.lung.org/media/press-releases/patient-and-caregiver-network-announcement. Accessed February 24, 2024.
4. 4.↵
   Center for Disease Control and Prevention. Chronic obstructive pulmonary disease includes chronic bronchitis and emphysema. Updated November 2023. Available at: https://www.cdc.gov/nchs/fastats/copd.htm. Accessed February 24, 2024.
5. 5.↵
   Center for Disease Control and Prevention. Most recent national asthma data. Updated May 2023. Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed February 24, 2024.
6. 6.↵
   Center for Disease Control and Prevention. Behavioral risk factor surveillance system (BRFSS), 2011–2020. Available at: https://www.cdc.gov/copd/data-and-statistics/national-trends.html. Accessed February 24, 2024.
7. 7.↵
   American Lung Association. COPD trends brief: burden. Available at: https://www.lung.org/research/trends-in-lung-disease/copd-trends-brief/copd-burden. Accessed February 24, 2024.
8. 8.↵
   Center for Disease Control and Prevention. Control asthma. Updated March 2022. Available at: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/sixeighteen/asthma/index.htm. Accessed February 24, 2024.
9. 9.↵
   1. Nurmagambetov T,
   2. Kuwahara R,
   3. Garbe P

   . The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc 2018;15(3):348-356.

   OpenUrlCrossRefPubMed
10. 10.↵
    Department of Health and Human Services. International prescription drug price comparisons: estimates using 2022 data. Published February 2024. Available at: https://aspe.hhs.gov/sites/default/files/documents/277371265a705c356c968977e87446ae/international-price-comparisons.pdf. Accessed May 5, 2024.
11. 11.↵
    PETERSON-KFF Health System Tracker. How do prescription drug costs in the United States compare to other countries? Published February 2022. Available at: https://www.healthsystemtracker.org/chart-collection/how-do-prescription-drug-costs-in-the-united-states-compare-to-other-countries. Accessed May 5, 2024.
12. 12.↵
    GoodRx. How much asthma inhalers cost and how to save. Published June 2020. Available at: https://www.goodrx.com/blog/heres-why-asthma-inhalers-are-so-expensive. Accessed February 24, 2024.
13. 13.↵
    1. Castaldi PJ,
    2. Rogers WH,
    3. Safran DG,
    4. Wilson IB

    . Inhaler costs and medication non-adherence among seniors with chronic pulmonary disease. Chest 2010;138(3):614-620.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Nekui F,
    2. Galbraith AA,
    3. Briesacher BA,
    4. Zhang F,
    5. Soumerai SB,
    6. Ross-Degnan D,
    7. et al

    . Cost-related medication non-adherence and its risk factors among Medicare beneficiaries. Med Care 2021;59(1):13-21.

    OpenUrlCrossRefPubMed
15. 15.↵
    Association for Accessible Medicine. Report: 2023 US generic and biosimilar medicines savings report. Available at: https://accessiblemeds.org/resources/reports/2023-savings-report#. Accessed February 24, 2024.
16. 16.↵
    Food and Drug Administration. How generic competition helps bring down drug prices. Updated October 2023. Available at: https://www.fda.gov/bout-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices. Accessed February 24, 2024.
17. 17.↵
    1. Lionberger R

    . Innovation for generic drugs: science and research under the generic drug user fee amendments of 2012. Clin Pharmacol Ther 2019;105(4):878-885.

    OpenUrlPubMed
18. 18.↵
    Food and Drug Administration. Generic competition and drug prices. Updated October 5, 2023. Available at: https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices. Accessed February 24, 2024.
19. 19.↵
    Food and Drug Administration. Draft guidance on fluticasone propionate; salmeterol xinafoate. Published September 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Fluticasone%20Proprionate_Salmeterol%20Xinafoate_21077_RC09-13.pdf. Accessed Feb 24, 2024.
20. 20.↵
    Food and Drug Administration. Draft guidance on albuterol sulfate. Published November 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf. Accessed February 24, 2024.
21. 21.↵
    1. Feldman WB,
    2. Tu SS,
    3. Alhiary R,
    4. Kesselheim AS,
    5. Wouters OJ

    . Manufacturer revenue on inhalers after expiration of primary patents, 2000–2021. JAMA 2023;329(1):87-89.

    OpenUrlPubMed
22. 22.↵
    1. Furlow B

    . US Senate committee investigates asthma inhaler prices. Lancet Respir Med 2024;12(4):270.

    OpenUrlPubMed
23. 23.↵
    Department of Health and Human Services. Why different purchasers pay different prices for prescription drugs. Published August 8, 2000. Available at: https://aspe.hhs.gov/why-different-purchasers-pay-different-prices-prescription-drugs. Accessed February 24, 2024.
24. 24.↵
    1. Ovsag K,
    2. Hydery S,
    3. Mousa S

    . Preferred drug lists: potential impact on health care economics. Vasc Health Risk Manag 2008;4(2):403-413.

    OpenUrlPubMed
25. 25.↵
    Centers for Medicare and Medicaid Services. Annual limits. Updated September 6, 2023. Available at: https://www.cms.gov/marketplace/private-health-insurance/annual-limits. Accessed March 1, 2023.
26. 26.↵
    1. Dolinar R,
    2. Kohn CG,
    3. Lavernia F,
    4. Nguyen E

    . The non-medical switching of prescription medications. Postgrad Med 2019;131(5):335-341.

    OpenUrl
27. 27.↵
    1. Nguyen E,
    2. Weeda ER,
    3. Sobieraj DM,
    4. Bookhart BK,
    5. Piech CT,
    6. Coleman CI

    . Impact of non-medical switching on clinical and economic outcomes, resource utilization, and medication-taking behavior: a systematic literature review. Curr Med Res Opin 2016;32(7):1281-1290.

    OpenUrlPubMed
28. 28.↵
    The Moran Company. Cost-motivated treatment changes in commercial claims: implications for non-medical switching. Updated August 2017. Available at: https://instituteforpatientaccess.org/wp-content/uploads/2018/05/Moran_Commercial-claims-analysis-report_Aug-2017.pdf. Accessed February 24, 2024.
29. 29.↵
    Massachusetts Medical Society. A crisis in health care: a call to action on physician burnout. 2018. Available at: https://www.massmed.org/Publications/Research,-Studies,-and-Reports/A-Crisis-in-Health-Care--A-Call-to-Action-on--Physician-Burnout. Accessed March 1, 2024.
30. 30.↵
    1. Hamel MB,
    2. Epstein A

    . Prior authorization programs for controlling drug spending. N Engl J Med 2004;351(21):2156-2158.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Johnston A,
    2. Asmar R,
    3. Dahlöf B,
    4. Hill K,
    5. Jones DA,
    6. Jordan J,
    7. et al

    . Generic and therapeutic substitution: a viewpoint of achieving best practice in Europe. Br J Clin Pharmacol 2011;72(5):727-730.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Daley-Yates P

    . Inhaled corticosteroids: potency, dose equivalence, and therapeutic index. Br J Clin Pharmacol 2015;80(3):372-380.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Kelly HW

    . Comparison of inhaled corticosteroids. Ann Pharmacother 1998;32(2):220-232.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Coleman C,
    2. Salam T,
    3. Duhig A,
    4. Patel AA,
    5. Cameron A,
    6. Voelker J,
    7. et al

    . Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume Medicare and Medicaid physician providers. J Mark Access Health Policy 2020;8(1):1829883

    OpenUrlPubMed
35. 35.↵
    1. Ye Q,
    2. He X-O,
    3. D’Urzo A

    . A review on the safety and efficacy of inhaled corticosteroids in asthma. Pulm Ther 2017;3(1):1-18.

    OpenUrl
36. 36.↵
    1. Axelsson I,
    2. Naumburg E,
    3. Prietsch SO,
    4. Zhang L

    . Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth (review). Cochrane Database Syst Rev 2019;6(6):CD010126.

    OpenUrlPubMed
37. 37.↵
    1. de Boer AH,
    2. Hagedoorn P,
    3. Hoppentocht M,
    4. Buttini F,
    5. Grasmeijer F,
    6. Frijlink HW

    . Dry powder inhalation: past, present, and future. Expert Opin Drug Deliv 2017;14(4):499-512.

    OpenUrlPubMed
38. 38.↵
    1. de Boer AH,
    2. Hagedoorn P,
    3. Grasmeijer F

    . Dry powder inhalation, part 2: the present and future. Expert Opin Drug Deliv 2022;19(9):1045-1059.

    OpenUrlPubMed
39. 39.↵
    1. Fink JB

    . Aerosol device selection: evidence to practice. Respir Care 2000;45(7):874-885.

    OpenUrlPubMed
40. 40.↵
    1. Gardenshire D,
    2. Nozart L,
    3. Hinski S

    . A guide to aerosol delivery devices, 5th edition. 2023. American Association for Respiratory Care. Available at: https://www.aarc.org/wp-content/uploads/2018/03/aersol-guides-for-rts.pdf. Accessed March 5, 2024.
41. 41.↵
    1. Hess D,
    2. Dhand R

    . Delivery of inhaled medication in adults. Updated November 6, 2023. Available at: https://medilib.ir/uptodate/show/552. Accessed March 5, 2024.
42. 42.↵
    1. Jabre N,
    2. Jassal M

    . Breath-actuated inhalers in childhood asthma. Contemp Pediatr 2018;36(9):8-10.

    OpenUrl
43. 43.↵
    1. Navaie M,
    2. Dembek C,
    3. Cho-Reyes S,
    4. Yeh K,
    5. Celli BR

    . Device use errors with soft mist inhalers: a global systematic literature review and meta-analysis. Chron Respir Dis 2020;17:1479973119901234.

    OpenUrlPubMed
44. 44.↵
    1. Baker JA,
    2. Houin PR

    . Comparison of national and global asthma management guiding documents. Respir Care 2023;68(1):114-128.

    OpenUrlAbstract/FREE Full Text
45. 45.↵
    Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention Updated 2023. https://ginasthma.org/2023-gina-main-report/.
46. 46.↵
    National Heart Lung and Blood Institute. 2020 focused updates to the asthma management guidelines. Published 2020. Available at: https://www.nhlbi.nih.gov/resources/2020-focused-updates-asthma-management-guidelines. Accessed February 25, 2024.
47. 47.↵
    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis, and management of chronic obstructive pulmonary disease. Updated 2024. Available at: https://goldcopd.org/2024-gold-report. Accessed February 25, 2024.
48. 48.↵
    1. Brocklebank D,
    2. Wright J,
    3. Cates C

    . Systematic review of clinical effectiveness of pressurized metered-dose inhalers versus other handheld inhaler devices for delivering corticosteroids in asthma. BMJ 2001;323323(7318):896-900.

    OpenUrl
49. 49.↵
    1. Cates CJ,
    2. Welsh EJ,
    3. Rowe BH

    . Holding chambers (spacers) versus nebulizers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013;2013(9):CD000052.

    OpenUrlPubMed
50. 50.↵
    1. Deerojanawong J,
    2. Manuyakorn W,
    3. Prapphal N,
    4. Harnruthakorn C,
    5. Sritippayawan S,
    6. Samransamruajkit R

    . Randomized controlled trial of salbutamol aerosol therapy via metered-dose inhaler spacer versus jet nebulizer in young children with wheezing. Pediatr Pulmonol 2005;39(5):466-472.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    1. Drblik S,
    2. Lapierre G,
    3. Thivierge R,
    4. Turgeon J,
    5. Gaudreault P,
    6. Cummins-McManus B,
    7. et al

    . Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurized metered-dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch Dis Child 2003;88(4):319-323.

    OpenUrlAbstract/FREE Full Text
52. 52.↵
    1. Dekhuijzen PN,
    2. Lavorini F,
    3. Usmani OS

    . Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat or HandiHaler. Patient Prefer Adherence 2016;10:1561-1572.

    OpenUrlPubMed
53. 53.↵
    1. Kocks J,
    2. Bosnic-Anticevich S,
    3. van Cooten J,
    4. Correia de Sousa J,
    5. Cvetkovski B,
    6. Dekhuijzen R,
    7. et al

    . Identifying critical inhalation technique errors in dry powder inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study. BMC Pulm Med 2023;23(1):302.

    OpenUrlPubMed
54. 54.↵
    1. Lee HY,
    2. Song JH,
    3. Won H-K,
    4. Park Y,
    5. Chung KB,
    6. Lim H-J,
    7. et al

    . Comparing inhaler use technique based on inhaler type in elderly patients with respiratory disease. Tuberc Respir Dis (Seoul) 2021;84(1):46-54.

    OpenUrlPubMed
55. 55.↵
    1. Schultz A,
    2. Le Souëf TJ,
    3. Venter A,
    4. Zhang G,
    5. Devadason SG,
    6. Le Souëf PN

    . Aerosol inhalation from spacers and valved holding chambers requires few tidal breaths for children. Pediatrics 2010;126(6):e1493-1498.

    OpenUrlCrossRefPubMed
56. 56.↵
    1. Beihn R,
    2. Doherty D

    . Why use a spacer with an inhaler? Comparative respiratory deposition of 99m Tc labeled particles of albuterol using a metered-dose inhaler, a metered-dose inhaler with Aerochamber spacer, and OptiChamber spacer in healthy human volunteers using gamma-scintigraphy. Published 1997. Available at: https://pediatrics.weill.cornell.edu/sites/default/files/why_use_a_spacer.pdf. Accessed May 7, 2024.
57. 57.↵
    1. Ohar JA,
    2. Ferguson GT,
    3. Mahler DA,
    4. Drummond MB,
    5. Dhand R,
    6. Pleasants RA,
    7. et al

    . Measuring peak inspiratory flow in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2022;17:79-92.

    OpenUrlPubMed
58. 58.↵
    1. Kulkarni VS

    1. Ali M

    . Dry powder inhalers: an overview. In: Kulkarni VS, editor. Handbook of noninvasive drug delivery systems. Elsevier; 2010:209-246.
59. 59.↵
    1. Anderson PJ

    . History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care 2005;50(9):1139-1150.

    OpenUrlAbstract/FREE Full Text
60. 60.↵
    1. Harjunen P,
    2. Lankinen T,
    3. Salonen H,
    4. Lehto VP,
    5. Jarvinen K

    . Effects of carriers and storage of formulation on the lung deposition of a hydrophobic and hydrophilic drug from a DPI. Int J Pharm 2003;263(1-2):151-163.

    OpenUrlPubMed
61. 61.↵
    1. Healy AM,
    2. Amaro MI,
    3. Paluch KJ,
    4. Tajber L

    . Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev 2014;75:32-52.

    OpenUrlCrossRefPubMed
62. 62.↵
    1. Cakmakli S,
    2. Ozdemir A,
    3. Firat H,
    4. Aypak C

    . An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease. J Taibah Univ Med Sci 2023;18(4):860-867.

    OpenUrlPubMed
63. 63.↵
    1. Amirav I,
    2. Newhouse MT,
    3. Mansour Y

    . Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005;39(5):447-451.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    1. Hua J-L,
    2. Ye X-F,
    3. Du C-L,
    4. Xie N,
    5. Zhang J-Q,
    6. Li M,
    7. et al

    . Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma. BMC Pulm Med 2021;21(1):302.

    OpenUrlPubMed
65. 65.↵
    1. Kamps AWA,
    2. Brand PLP,
    3. Roorda RJ

    . Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 2004;37(1):65-70.

    OpenUrlPubMed
66. 66.↵
    1. Haughney J,
    2. Price D,
    3. Barnes NC,
    4. Virchow JC,
    5. Roche N,
    6. Chrystyn H

    . Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104(9):1237-1245.

    OpenUrlCrossRefPubMedWeb of Science
67. 67.↵
    1. Lavorini F,
    2. Janson C,
    3. Braido F,
    4. Stratelis G,
    5. Lokke A

    . What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis 2019;13:1753466619884532.

    OpenUrlPubMed
68. 68.↵
    1. Usmani OS

    . Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag 2019;15:461-472.

    OpenUrlCrossRefPubMed
69. 69.↵
    1. Johnson D

    . Interfaces to connect the HandiHaler and aerolizer powder inhalers to a tracheostomy tube. Respir Care 2007;52(2):166-170.

    OpenUrlAbstract/FREE Full Text
70. 70.↵
    1. Pornputtapitak W,
    2. El-Gendy N

    . Dry powder inhaler in mechanical ventilation and influence of ventilator circuit–related factors on aerosol delivery during mechanical ventilation. Pharm Sci Asia 2019;46:1-11.

    OpenUrl
71. 71.↵
    1. Marguet C,
    2. Couderc L,
    3. Le Roux P,
    4. Jeannot E,
    5. Lefay V,
    6. Mallet E

    . Inhalation treatment: errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children. Pediatr Allergy Immunol 2001;12(4):224-230.

    OpenUrlCrossRefPubMedWeb of Science
72. 72.↵
    Aetna. Plan for your best health: 2024 Aetna Pharmacy Drug Guide, Aetna standard plan. Updated January 1, 2024. Available at: https://fm.formularynavigator.com/FBO/41/2024_Aetna_Standard_Plan_.pdf. Accessed March 1, 2024.
73. 73.↵
    United Healthcare. Your 2024 prescription drug list. Updated January 1, 2024. Available at: https://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/pharmacy-pdl-premium-jan-2024.pdf. Accessed February 24, 2024.
74. 74.↵
    1. Leving MT,
    2. Bosnic-Anticevich S,
    3. van Cooten J,
    4. de Sousa JC,
    5. Cvetkovski B,
    6. Dekhuijzen R,
    7. et al

    . Clinical recommendations for dry powder inhaler use in the management of COPD in primary care. NPJ Prim Care Respir Med 2022;32(1):59.

    OpenUrlPubMed
75. 75.↵
    1. Shukar S,
    2. Zahoor F,
    3. Hayat K,
    4. Saeed A,
    5. Gillani AH,
    6. Omer S,
    7. et al

    . Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol 2021;12:693426.

    OpenUrlCrossRefPubMed
76. 76.↵
    1. Sen-Crowe B,
    2. McKenney M,
    3. Elkbuli A

    . Medication shortages during the COVID-19 pandemic: saving more than COVID lives. Am J Emerg Med 2021;45:557-559.

    OpenUrlPubMed
77. 77.↵
    1. Bookwalter C

    . Drug shortages amid the COVID-19 pandemic. US Pharmacology 2023;46(2):25-28.

    OpenUrl
78. 78.↵
    Federal Trade Commission. HHS seek public comment on generic drug shortages and competition amongst powerful middlemen. Published February 14, 2024. Available at:https://www.ftc.gov/news-events/news/press-releases/2024/02/ftc-hhs-seek-public-comment-generic-drug-shortages-competition-amongst-powerful-middlemen. Accessed March 18, 2024.
79. 79.↵
    Lincoln Journal Star. Nebraska bill would limit costs for EpiPens and inhalers. Published February 14, 2024. Available at: https://journalstar.com/news/state-regional/government-politics/nebraska-bill-to-limit-costs-of-epipens-inhalers-receives-support-except-from-insurance-providers/article_2f192d28-9bb0-5a76-8ff9-afe8ac02e19a.html. Accessed March 12, 2024.
80. 80.↵
    Minnesota House of Representatives. Minnesota legislature caps the cost of insulin, asthma inhalers, and EpiPens. Published May 17, 2023. Available at: https://www.house.mn.gov/members/Profile/News/15518/37223. Accessed Mar 12, 2024.
81. 81.↵
    WICS/WCCU. State senator pushes to cap prescription inhaler costs at $25 for insured individuals. Published March 7, 2024. Available at: https://newschannel20.com/news/local/state-senator-pushes-to-cap-prescription-inhaler-costs-at-25-for-insured-individuals. Accessed March 12, 2024.
82. 82.↵
    Asthma and Allergy Network. Drug companies step forward with voluntary price caps on inhalers. Published March 21, 2024. Available at: https://allergyasthmanetwork.org/news/drug-company-asthma-inhaler-price-cap. Accessed April 29, 2024.
83. 83.↵
    Allergy Asthma Foundation of America. AAFA statement on asthma inhaler price caps. Published March 8, 2024. Available at: https://aafa.org/aafa-statement-on-asthma-inhaler-price-caps/#:∼:text=Boehringer%20Ingelheim%20announced%20it%20will,commercial%20insurance%20or%20no%20insurance. Accessed March 12, 2024.
84. 84.↵
    1. Rogueda P,
    2. Traini D

    . The future of inhalers: how can we improve drug delivery in asthma and COPD? Expert Rev Respir Med 2016;10(10):1041-1044.

    OpenUrlPubMed
85. 85.↵
    1. Domínguez-Ortega J,
    2. Mullol J,
    3. Álvarez Gutiérrez FJ,
    4. Miguel-Blanco C,
    5. Castillo JA,
    6. Olaguibel JM,
    7. et al

    . The effect of biologics in lung function and quality of life of patients with united airways disease: a systematic review. J Allergy Clin Immunol Glob 2024;3(1):100174.

    OpenUrlPubMed
86. 86.↵
    1. Fidler L,
    2. Green S,
    3. Wintemute K

    . Pressurized metered-dose inhalers and their impact on climate change. CMAJ 2022;194(12):E460.

    OpenUrlFREE Full Text
87. 87.↵
    Environmental Protection Agency. Phaseout of ozone-depleting substances (ODS). Updated February 17, 2024. Available at: https://www.epa.gov/ods-phaseout. Accessed February 26, 2024.
88. 88.↵
    Environmental Protection Agency. Summary of the Clean Air Act. Available at: https://www.epa.gov/laws-regulations/summary-clean-air-act. Accessed February 26, 2024.
89. 89.↵
    Federal Register. Use of ozone-depleting substances; removal of essential-use designations. Published April 4, 2005. Available at: https://www.federalregister.gov/documents/2005/04/04/05-6599/use-of-ozone-depleting-substances-removal-of-essential-use-designation. Accessed February 26, 2024.
90. 90.↵
    1. Jena AB,
    2. Ho O,
    3. Goldman DP,
    4. Karaca-Mandic P

    . The impact of the US Food and Drug Administration chlorofluorocarbon ban on out-of-pocket costs and use of albuterol inhalers among individuals with asthma. JAMA Intern Med 2015;175(7):1171-1179.

    OpenUrlPubMed
91. 91.↵
    1. Janson C,
    2. Henderson R,
    3. Lofdahl M,
    4. Hedberg M,
    5. Sharma R,
    6. Wilkinson AJK

    . Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax 2020;75(1):82-84.

    OpenUrlAbstract/FREE Full Text
92. 92.↵
    Environmental Protection Agency. Market characterization of the US metered-dose inhaler industry. Published September 2021. Available at: https://www.epa.gov/sites/default/files/2021-03/documents/epa-hq-oar-2021-0044-0002_attachment_1-mdis.pdf. Accessed February 26. 2024.
93. 93.↵
    Environmental Protection Agency. Phasedown of hydrofluorocarbons. Published July 6, 2021. Available at: https://www.apha.org/-/media/Files/PDF/advocacy/TestimonyAndComments/210706_EPA_HFC_phasedown.ashx. Accessed February 26, 2024.